Cantor Fitzgerald Reiterates Neutral Rating for uniQure (NASDAQ:QURE)

Posted by Grant Hamersma on Mar 2nd, 2026

uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at Cantor Fitzgerald in a report issued on Monday, MarketBeat reports. They currently have a $9.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential downside of 9.31% from the stock’s current price.

Several other equities analysts have also issued reports on QURE. Chardan Capital reiterated a “buy” rating and issued a $53.00 price target on shares of uniQure in a research note on Thursday, December 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Wells Fargo & Company dropped their target price on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. Barclays assumed coverage on shares of uniQure in a report on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 price target on the stock. Finally, Wolfe Research initiated coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating for the company. Nine analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $52.42.

View Our Latest Stock Report on QURE

uniQure Stock Performance

Shares of QURE stock traded down $5.71 during midday trading on Monday, hitting $9.92. 10,250,327 shares of the company were exchanged, compared to its average volume of 2,609,414. uniQure has a 52 week low of $7.76 and a 52 week high of $71.50. The firm has a market capitalization of $618.19 million, a P/E ratio of -2.21 and a beta of 0.66. The firm’s 50 day moving average price is $23.46 and its two-hundred day moving average price is $29.80. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12.

uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, equities research analysts anticipate that uniQure will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 12,378 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $295,339.08. Following the sale, the chief executive officer owned 639,076 shares of the company’s stock, valued at $15,248,353.36. The trade was a 1.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Christian Klemt sold 6,217 shares of uniQure stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $148,337.62. Following the completion of the sale, the chief financial officer directly owned 211,513 shares of the company’s stock, valued at $5,046,700.18. The trade was a 2.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 50,598 shares of company stock worth $1,248,588. Company insiders own 4.79% of the company’s stock.

Institutional Trading of uniQure

A number of large investors have recently made changes to their positions in the company. Private Trust Co. NA acquired a new stake in uniQure in the third quarter valued at $28,000. Torren Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth about $28,000. Jones Financial Companies Lllp lifted its stake in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter valued at $48,000. Finally, Smartleaf Asset Management LLC purchased a new position in shares of uniQure in the 4th quarter valued at $48,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting uniQure

Here are the key news stories impacting uniQure this week:

Positive Sentiment: uniQure reported Q4 EPS of ($0.56) which beat the consensus loss (~$0.93) and posted revenue of $5.57M (above estimates), showing somewhat better near‑term operating results than expectations. uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Neutral Sentiment: Company published full 2025 results and a corporate update and said it held a Type A meeting with the FDA and is evaluating Phase III development considerations; uniQure plans to request a follow‑up Type B meeting in Q2 to clarify next steps. uniQure Announces 2025 Financial Results and Provides Recent Company Updates
Neutral Sentiment: Market commentary pieces are reassessing uniQure’s valuation and outlook given the new regulatory focus; these analyses may increase trading volume and volatility as investors digest longer approval timelines. Assessing uniQure (QURE) After Sharp Share Price Slide And Gene Therapy Regulatory Focus
Negative Sentiment: FDA told uniQure its AMT‑130 early‑to‑mid stage data are insufficient to support a marketing application and urged a new randomized trial for the Huntington’s disease gene therapy — a major setback that will likely delay approval, increase development cost and push out potential revenue. FDA tells UniQure study data insufficient for brain disorder therapy application
Negative Sentiment: News outlets report the FDA decision sent QURE shares plunging (reports of ~40–45% premarket declines), reflecting investor concern about a materially longer path to commercialization for AMT‑130. uniQure Stock Plunges 40% After FDA Shocker
Negative Sentiment: Multiple securities‑class action lawsuits and law‑firm solicitations allege disclosure failures tied to AMT‑130; ongoing litigation increases legal risk and could be a drag on investor sentiment and resources. uniQure N.V. Sued for Securities Law Violations

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.